What is the specific mechanism of action of Sorafenib/Nexavar?

Sorafenib/Nexavar (Sorafenib) is an oral small molecule multi-target tyrosine kinase inhibitor. Its unique mechanism of action makes it play an important role in the treatment of a variety of solid tumors. The drug mainly targets the angiogenesis signaling pathway, including vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR), thereby inhibiting tumor angiogenesis. This mechanism is particularly critical in the treatment of hepatocellular carcinoma, renal cell carcinoma, and thyroid cancer, because these tumors highly rely on angiogenesis to maintain rapid growth.

In addition, sorafenib can also directly act onRAF kinases, including c-RAF and B-RAF, inhibiting tumor cell proliferation and promoting apoptosis by blocking the RAS/RAF/MEK/ERK signaling pathway. The dual mechanism of action enables sorafenib to both slow tumor growth and reduce angiogenesis, providing patients with advanced tumors with the possibility of sustained tumor control. This compound mechanism is also an important reason why it can be recognized in liver cancer, kidney cancer and some thyroid cancers.

In clinical practice, the efficacy of sorafenib is closely related to its blood concentration, so the continuity of oral administration is very important. After being absorbed orally, the drug is distributed to the tumor and its microenvironment in the body, and achieves long-term control of the tumor by continuously inhibiting the signaling pathway. Tolerability and side effect management are also related to its mechanism of action. For example, hand-foot skin reactions may be related to inhibition of vascular endothelial function, while fluctuations in liver function may result from hepatocyte sensitivity to inhibition of the RAF pathway.

Overall, sorafenib achieves comprehensive management of advanced solid tumors by inhibiting angiogenesis and tumor proliferation signals at multiple targets. Its mechanism of action not only explains the clinical efficacy of the drug, but also provides a theoretical basis for combined immunotherapy or other targeted drugs, providing more possibilities for individualized treatment of patients.

Reference materials:https://www.nexavar.com/